Markets:

Overview

News

Currencies

International

Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

63.35 +2.58 (+4.25%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why Cytokinetics Stock Was a Nearly 5% Winner Today ↗

December 20, 2024

Via The Motley Fool

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

November 08, 2024

Via Benzinga

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 09, 2024

Via Benzinga

Analysts Think There's Still Time to Get in on Edgewise, Up 332%

September 25, 2024

Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?

Via MarketBeat

Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗

September 19, 2024

Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.

Via Investor's Business Daily

Peering Into Cytokinetics's Recent Short Interest ↗

June 07, 2024

Via Benzinga

(CYTK) - Analyzing Cytokinetics's Short Interest ↗

May 01, 2024

Via Benzinga

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study ↗

September 09, 2024

Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerability, and dose-linearity. Phase 2 trial expected to start Q4 2024.

Via Benzinga

CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024 ↗

August 08, 2024

CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal? ↗

July 11, 2024

CEO Robert Blum says there are key components to the funding arrangement with Royalty Pharma that investors are missing.

Via Investor's Business Daily

7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗

June 26, 2024

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

Via InvestorPlace

June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗

June 05, 2024

Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.

Via InvestorPlace

Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views ↗

May 23, 2024

Via Benzinga

Topics Earnings Stocks

Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe ↗

May 23, 2024

Unlock the latest on Royalty Pharma plc & Cytokinetics Inc.'s strategic funding collaboration for aficamten's commercialization and cardiovascular pipeline expansion.

Via Benzinga

8 Health Care Stocks Whale Activity In Today's Session ↗

May 23, 2024

Via Benzinga

Stocks Mixed Amid Flood Of Economic Data ↗

May 23, 2024

The Nasdaq is up triple digits midday, trading at fresh record highs thanks to Nvidia's post-earnings pop.

Via Talk Markets

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 23, 2024

Via Benzinga

Gold Falls Sharply; US Composite PMI Surges In May ↗

May 23, 2024

Via Benzinga

Why Cytokinetics (CYTK) Shares Are Falling ↗

May 23, 2024

Cytokinetics shares are trading lower by 15.8% during Thursday's session. The company announced the pricing of a public offering of 9,803,922 shares.

Via Benzinga

Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗

May 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 23, 2024

Via Benzinga

NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 23, 2024

Via Benzinga

VF Corp Posts Weak Q4 Results, Joins NetEase, Cytokinetics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 22, 2024

Via Benzinga

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22, 2024

From Royalty Pharma plc; Cytokinetics

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

May 17, 2024

Via Benzinga

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day ↗

May 13, 2024

The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.

Via Investor's Business Daily

CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

CYTK stock results show that Cytokinetics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare ↗

May 07, 2024

Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.

Via InvestorPlace

3 Biotech Stocks to Buy on the Dip: April 2024 ↗

April 26, 2024

With medical innovation being a resilient space, investors can have confidence with these biotech stocks to buy on the dip.

Via InvestorPlace

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

All News about Cytokinetics, Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today